Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the voting results from its annual and special meeting of shareholders held on September 22, 2026. According to the press release, 46,452,598 common shares were represented at the meeting, representing 63.58% of the company's outstanding shares as of the record date. Shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors, and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So as directors. Additionally, shareholders approved changing the company's legal name from Cybin Inc. to Helus Pharma Inc., effective October 1. This legal name change follows the adoption of the Helus Pharma business name on January 5 and reflects the company's anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
The name change is more than a rebranding; it underscores Helus Pharma's strategic shift toward commercialization. The company is currently developing HLP003, a proprietary novel serotonergic agonist (NSA), in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Helus Pharma is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. With an extensive research portfolio of investigational NSAs, the company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Operating in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is positioning itself as a leader in the mental health treatment landscape.
The approval of the name change and the election of a seasoned board of directors are critical steps as Helus Pharma prepares for the next phase of growth. The company's focus on novel serotonergic agonists, which are designed to activate serotonin pathways believed to promote neuroplasticity, could potentially offer durable improvements in mental health. With class-leading data, Helus Pharma aims to improve the treatment landscape. For more information about Helus Pharma, visit www.helus.com.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. Investors can view the full press release at https://nnw.fm/H4DVg.
